Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zena Willsmore"'
Autor:
Robert J Harris, Zena Willsmore, Roman Laddach, Silvia Crescioli, Jitesh Chauhan, Anthony Cheung, Anna Black, Jenny L. C. Geh, Alastair D MacKenzie Ross, Ciaran Healy, Sophia Tsoka, James Spicer, Katie E Lacy, Sophia N Karagiannis
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
B cells are emerging as key players of anti-tumor adaptive immune responses. We investigated regulatory and pro-inflammatory cytokine-expressing B cells in patients with melanoma by flow cytometric intracellular cytokine, CyTOF, transcriptomic, immun
Externí odkaz:
https://doaj.org/article/5ee960605c5a4a89bebd0943b4e44eca
Autor:
Rebecca Adams, Gabriel Osborn, Bipashna Mukhia, Roman Laddach, Zena Willsmore, Alicia Chenoweth, Jenny L C Geh, Alastair D MacKenzie Ross, Ciaran Healy, Linda Barber, Sophia Tsoka, Victoria Sanz-Moreno, Katie E Lacy, Sophia N Karagiannis
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by
Externí odkaz:
https://doaj.org/article/96ec4ae35e51463cbf1b5510ddb115e2
Autor:
Rebecca Adams, Jack E M Coumbe, Ben G T Coumbe, Jennifer Thomas, Zena Willsmore, Marija Dimitrievska, Monica Yasuzawa-Parker, Maximilian Hoyle, Suhaylah Ingar, Jenny L C Geh, Alastair D MacKenzie Ross, Ciaran Healy, Sophie Papa, Katie E Lacy, Sophia N Karagiannis
Publikováno v:
Adams, R, Coumbe, J E M, Coumbe, B G T, Thomas, J, Willsmore, Z, Dimitrievska, M, Yasuzawa-Parker, M, Hoyle, M, Ingar, S, Geh, J, MacKenzie Ross, A, Healy, C, Papa, S, Lacy, K E & Karagiannis, S N 2022, ' BRAF inhibitors and their immunological effects in malignant melanoma ', Expert Review Of Clinical Immunology, vol. 18, no. 4, pp. 347-362 . https://doi.org/10.1080/1744666X.2022.2044796
Introduction: The treatment of cutaneous melanoma has been revolutionized by the development of small-molecule inhibitors targeting the MAPK pathway, including inhibitors of BRAF (BRAFi) and MEK (MEKi), and immune checkpoint blockade antibodies, occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ab9be0d9ed21e170e39875d482bfb4
https://pubmed.ncbi.nlm.nih.gov/35195495
https://pubmed.ncbi.nlm.nih.gov/35195495
Primary extramedullary plasmacytoma is rare monoclonal proliferation of plasma cells, which arise in various nonosseous anatomic locations without detectable underlying systemic disease. Historically, cutaneous infiltrates rich in mature neoplastic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dbed1df916021717b3bc82e4ff321a5
https://www.zora.uzh.ch/id/eprint/209681/
https://www.zora.uzh.ch/id/eprint/209681/
Autor:
Zena Willsmore, Bina Menon, Catherine H. Smith, R T Woolf, Andrew Pink, Catherine D Hughes, Bruce Kirkham
Publikováno v:
Rheumatology. 59
Background Dupilumab is a recombinant human monoclonal antibody that inhibits signalling of interleukin-4 and interleukin-13. It has NICE approval for use in patients with moderate to severe atopic eczema who have failed at least one standard therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e94d8fd1b178020cdb1170a0f77e8d0a
https://doi.org/10.1093/rheumatology/keaa111.259
https://doi.org/10.1093/rheumatology/keaa111.259